Phesgo 600 mg/600 mg 10 mL

Description

Phesgo 600 mg/600 mg 10 mL (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a medicine given together with other cancer medications for the treatment of adults with metastasized HER2-positive breast cancer and adult patients with early HER2-positive breast cancer. The drug, which is used together with other cancer drugs in the treatment of breast cancer, is produced by Roche. It is approved by the European Medical Agency (EMA) and the Food and Drug Administration (FDA) and is administered as subcutaneous injection.